Dimitrios Bampatsias

Dimitrios Bampatsias

Auto-generated profile, based on publicly available information

Dimitrios Bampatsias

Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in JACC: Heart Failure
Verified
Journal Article
Closed access
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
SFStefano Figliozzi
Stefano Figliozzi
KPKonstantinos Pateras
Konstantinos Pateras
FNFlavia Nicoli
Flavia Nicoli
DBDimitrios Bampatsias
Dimitrios Bampatsias
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto

11 November 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EAEvmorfia Aivalioti
Evmorfia Aivalioti
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
STSimon Tual-Chalot
Simon Tual-Chalot
DBDimitrios Bampatsias
Dimitrios Bampatsias
DDDimitrios Delialis
Dimitrios Delialis
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
Epidemiological evidence suggests the presence of common risk factors for the development and prognosis of both cardio- and cerebrovascular diseases, including stroke, Alzheimer's disease, vascular dementia, heart, and peripheral vascular diseases. Accumulation of harmful blood signals may induce organotypic endothelial dysfunction affecting blood–brain barrier function and vascular health in age-related diseases. Genetic-, age-, lifestyle- or cardiovascular therapy–associated imbalance of amyloid-beta (Aβ) peptide metabolism in the brain and periphery may be the missing link between age-related neurocardiovascular diseases. Genetic polymorphisms of genes related to Aβ metabolism, lifestyle modifications, drugs used in clinical practice, and Aβ-specific treatments may modulate Aβ levels, affecting brain, vascular, and cardiac diseases. This narrative review elaborates on the effects of interventions on Aβ metabolism in the brain, cerebrospinal fluid, blood, and peripheral heart or vascular tissues. Implications for clinical applicability, gaps in knowledge, and future perspectives of Aβ as the link among age-related neurocardiovascular diseases are also discussed.

3 May 2023 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
Ioannis LeontsinisIoannis Leontsinis
Ioannis Leontsinis
DFDimitrios Farmakis
Dimitrios Farmakis
DADimitrios Avramidis
Dimitrios Avramidis
EAEirini Andrikou
Eirini Andrikou
AVAngeliki Valatsou
Angeliki Valatsou
KTKonstantinos Tsioufis
Konstantinos Tsioufis
Cardiovascular disease is commonly accompanied by renal dysfunction. Multimorbidity in hospitalized patients impacts unfavorably on prognosis and hospital stay. We aimed to illustrate the contemporary burden of cardiorenal morbidity across inpatient cardiology care in Greece. The Hellenic Cardiorenal Morbidity Snapshot (HECMOS) used an electronic platform to collect demographic and clinically relevant information about all patients hospitalized on the 3rd of March 2022 in Greece. The participating institutions covered all levels of inpatient cardiology care and most of the country's territories in order to collect a real-world, nation representative sample. 923 patients (males 68.4%, median age 73ys ± 14.8) were admitted in 55 different cardiology departments. 57.7% of the sample were older than 70 years of age. Hypertension was highly prevalent, present in 66% of cases. History of chronic HF, DM, AF and CKD was present in 38%, 31.8%, 30% and 26% respectively. 64.1% of the sample exhibited at least one of these four entities. Accordingly, a combination of at least 2 of them was recorded in 38.7%, of at least three in 18.2% whereas 4.3% of the sample combined all four morbid conditions in their past medical history. The most common combination was the coexistence of HF-AF accounting for 20.6% of the sample. 9 out of 10 non-electively admitted patients were hospitalized due to acute HF (39.9%), ACS (33.5%) or tachyarrhythmias (13.2%). HECMOS participants carried a remarkable burden of cardio-reno-metabolic disease. HF in conjunction with AF were found to be the most prevalent combination among the studied cardiorenal nexus of morbidities in the whole study population.

23 March 2025 in Heart
Verified
Journal Article
Closed access
PDF file
DBDimitrios Bampatsias
Dimitrios Bampatsias
AWAbdirahman Wardhere
Abdirahman Wardhere
LZLawrence Zeldin
Lawrence Zeldin
AMAlfonsina Mirabal-Santos
Alfonsina Mirabal-Santos
AWAriel Y Weinsaft
Ariel Y Weinsaft
MMMathew S Maurer
Mathew S Maurer
Background Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience worsening cardiac disease (WCD) despite disease-modifying treatment. However, a strict definition is lacking. Recent studies have shown that N-terminal pro-B-natriuretic peptide (NT-proBNP increase), or intensification of oral diuretics, is associated with increased mortality risk. Aim To describe the pattern of WCD at 1 year in patients with ATTR-CM on tafamidis and explore the association with mortality and cardiovascular (CV) hospitalisation. Methods Patients diagnosed with ATTR-CM at Columbia University after 2018 who were treated with tafamidis were enrolled in the study. WCD was defined as: increase in NT-proBNP >700 pg/mL and >30% from baseline or oral diuretic intensification (ODI) or both. Survival and CV hospitalisation risk analysis was performed using Kaplan-Meier curves, Cox regression and competing risk regression adjusted for age, genotype and disease severity by the National Amyloidosis Centre (NAC) stage. Results A total of 238 patients were enrolled, 100 (42%) of whom showed WCD at 1 year. WCD was associated with increased mortality risk (log rank, p<0.0001, HR=1.91 (1.10–3.32), p=0.023, after adjustment for age, genotype and baseline NAC stage). In competing risk analysis, WCD was associated with increased risk for CV-related hospitalisation (HR=1.8 (1.17–2.99, p=0.009)) after adjustment for age, genotype and baseline NAC stage. Conclusions NT-proBNP increase and ODI can serve as markers of WCD and predict mortality and CV hospitalisations in a cohort of patients taking tafamidis.

1 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DDD Delialis
D Delialis
GMG Mavraganis
G Mavraganis
ADA Dimoula
A Dimoula
EAE Ajdini
E Ajdini
DBD Bampatsias
D Bampatsias
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
Depression and atherosclerotic cardiovascular disease (ASCVD) are commonly clustered in affected patients. Endothelial dysfunction is an early marker of ASCVD while also reported in patients with depression. Emerging evidence suggests that selective serotonin receptor inhibitors (SSRIs) may improve endothelial function. However, clinical studies assessing flow-mediated dilation (FMD), the gold-standard method to evaluate conduit artery endothelial function, in response to SSRIs treatment included limited number of patients and did not provide consistent results. In the present study we aim to evaluate the effect of SSRIs treatment on endothelial function assessed by longitudinal changes in FMD. We performed a systematic review to retrieve and subsequently meta-analyze eligible studies in patients with depression who received SSRIs and had available measurements of FMD change before and after treatment. In 5 studies and 323 individuals in total, SSRIs were associated with increased FMD at the end of follow-up compared to baseline measurement (pooled mean change 1.97%, 95% CI 0.17, 3.77, P=0.032, I2=87.4%). These results did not substantially change when analysis was restricted to patients with history of atherosclerotic cardiovascular disease (ASCVD). Similarly, FMD changes were higher in individuals receiving SSRIs compared to not-treated subjects (pooled mean difference 2.5%. 95% CI 0.7, 4.2, P<0.001, I2=82.7%). Substantial heterogeneity regarding with respect to follow-up duration, demographics, and SSRIs agents. SSRIs significantly improve FMD, the gold-standard marker of endothelial function. Further investigation is warranted for the role of FMD as a possible therapeutic biomarker in patients with depression and established or subclinical ASCVD. Prospero registration: CRD42021252241 Type of funding sources: None. Figure 1